Drugs / TY027
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04429529 | Jun → Nov 2020 | COVID-19 | Tychan Pte Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04649515 | Dec 2020 → Mar 2022 | COVID-19 | Tychan Pte Ltd. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TY027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04649515 ↗ |
| Modality | Monoclonal antibody | “SARS-CoV-2 Monoclonal Antibody (mAb)” NCT04649515 ↗ |
| Route | Intravenous | “administered with 0.5 mg/kg of TY027 via IV infusion” NCT04429529 ↗ |